Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Neuroblastoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
CNS Tumor (533
)
Brain Cancer (525
)
Glioma (484
)
Pituitary Gland Carcinoma (10
)
Meningioma (8
)
CNS Tumor (533
)
Brain Cancer (525
)
Glioma (484
)
Pituitary Gland Carcinoma (10
)
Meningioma (8
)
›
Associations
(48)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ALK R1275Q
Neuroblastoma
ALK R1275Q
Neuroblastoma
lorlatinib
Sensitive: C4 – Case Studies
Nat Commun - 3 weeks (New C4)
lorlatinib
Sensitive
:
C4
Nat Commun - 3wk
lorlatinib
Sensitive: C4 – Case Studies
Nat Commun - 3 weeks
lorlatinib
Sensitive
:
C4
Nat Commun - 3 weeks - (New C4)
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
dinutuximab beta
Sensitive: A1 - Approval
dinutuximab beta
Sensitive
:
A1
dinutuximab beta
Sensitive: A1 - Approval
dinutuximab beta
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
melphalan
Sensitive: A1 - Approval
melphalan
Sensitive
:
A1
melphalan
Sensitive: A1 - Approval
melphalan
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
dinutuximab
Sensitive: A1 - Approval
dinutuximab
Sensitive
:
A1
dinutuximab
Sensitive: A1 - Approval
dinutuximab
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
naxitamab
Sensitive: A1 - Approval
naxitamab
Sensitive
:
A1
naxitamab
Sensitive: A1 - Approval
naxitamab
Sensitive
:
A1
ALK positive
Neuroblastoma
ALK positive
Neuroblastoma
lorlatinib
Sensitive: C1 - Off-label
lorlatinib
Sensitive
:
C1
lorlatinib
Sensitive: C1 - Off-label
lorlatinib
Sensitive
:
C1
ALK positive
Neuroblastoma
ALK positive
Neuroblastoma
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
ALK R1275Q
Neuroblastoma
ALK R1275Q
Neuroblastoma
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
ATRX mutation
Neuroblastoma
ATRX mutation
Neuroblastoma
AZD1775
Sensitive: C3 – Early Trials
AZD1775
Sensitive
:
C3
AZD1775
Sensitive: C3 – Early Trials
AZD1775
Sensitive
:
C3
ALK rearrangement + ALK R1275Q + TP53 mutation
Neuroblastoma
ALK rearrangement + ALK R1275Q + TP53 mutation
Neuroblastoma
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
PGBD5 overexpression
Neuroblastoma
PGBD5 overexpression
Neuroblastoma
cisplatin
Sensitive: D – Preclinical
cisplatin
Sensitive
:
D
cisplatin
Sensitive: D – Preclinical
cisplatin
Sensitive
:
D
PGBD5 overexpression
Neuroblastoma
PGBD5 overexpression
Neuroblastoma
AZD6738
Sensitive: D – Preclinical
AZD6738
Sensitive
:
D
AZD6738
Sensitive: D – Preclinical
AZD6738
Sensitive
:
D
PGBD5 underexpression
Neuroblastoma
PGBD5 underexpression
Neuroblastoma
AZD6738
Sensitive: D – Preclinical
AZD6738
Sensitive
:
D
AZD6738
Sensitive: D – Preclinical
AZD6738
Sensitive
:
D
ALK R1275Q
Neuroblastoma
ALK R1275Q
Neuroblastoma
TAE-684
Resistant: D – Preclinical
TAE-684
Resistant
:
D
TAE-684
Resistant: D – Preclinical
TAE-684
Resistant
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
panobinostat + GSK2816126
Sensitive: D – Preclinical
panobinostat + GSK2816126
Sensitive
:
D
panobinostat + GSK2816126
Sensitive: D – Preclinical
panobinostat + GSK2816126
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
OTX015
Sensitive: D – Preclinical
OTX015
Sensitive
:
D
OTX015
Sensitive: D – Preclinical
OTX015
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
JQ-1 + panobinostat
Sensitive: D – Preclinical
JQ-1 + panobinostat
Sensitive
:
D
JQ-1 + panobinostat
Sensitive: D – Preclinical
JQ-1 + panobinostat
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
brigatinib
Resistant: D – Preclinical
brigatinib
Resistant
:
D
brigatinib
Resistant: D – Preclinical
brigatinib
Resistant
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
crizotinib
Resistant: D – Preclinical
crizotinib
Resistant
:
D
crizotinib
Resistant: D – Preclinical
crizotinib
Resistant
:
D
ALK F1174L
Neuroblastoma
ALK F1174L
Neuroblastoma
crizotinib
Resistant: D – Preclinical
crizotinib
Resistant
:
D
crizotinib
Resistant: D – Preclinical
crizotinib
Resistant
:
D
ALK F1174L
Neuroblastoma
ALK F1174L
Neuroblastoma
AZD3463
Sensitive: D – Preclinical
AZD3463
Sensitive
:
D
AZD3463
Sensitive: D – Preclinical
AZD3463
Sensitive
:
D
ALK F1174L
Neuroblastoma
ALK F1174L
Neuroblastoma
alectinib
Sensitive: D – Preclinical
alectinib
Sensitive
:
D
alectinib
Sensitive: D – Preclinical
alectinib
Sensitive
:
D
ALK amplification
Neuroblastoma
ALK amplification
Neuroblastoma
alectinib
Sensitive: D – Preclinical
alectinib
Sensitive
:
D
alectinib
Sensitive: D – Preclinical
alectinib
Sensitive
:
D
ALK F1245C
Neuroblastoma
ALK F1245C
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
lorlatinib
Sensitive
:
D
lorlatinib
Sensitive: D – Preclinical
lorlatinib
Sensitive
:
D
ALK F1174C
Neuroblastoma
ALK F1174C
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
lorlatinib
Sensitive
:
D
lorlatinib
Sensitive: D – Preclinical
lorlatinib
Sensitive
:
D
ALK F1174L
Neuroblastoma
ALK F1174L
Neuroblastoma
TAE-684
Sensitive: D – Preclinical
TAE-684
Sensitive
:
D
TAE-684
Sensitive: D – Preclinical
TAE-684
Sensitive
:
D
MYCN amplification + ALK rearrangement
Neuroblastoma
MYCN amplification + ALK rearrangement
Neuroblastoma
brigatinib
Sensitive: D – Preclinical
brigatinib
Sensitive
:
D
brigatinib
Sensitive: D – Preclinical
brigatinib
Sensitive
:
D
MYCN amplification + ALK F1174V
Neuroblastoma
MYCN amplification + ALK F1174V
Neuroblastoma
brigatinib
Sensitive: D – Preclinical
brigatinib
Sensitive
:
D
brigatinib
Sensitive: D – Preclinical
brigatinib
Sensitive
:
D
MYCN amplification + ALK F1174V
Neuroblastoma
MYCN amplification + ALK F1174V
Neuroblastoma
crizotinib
Sensitive: D – Preclinical
crizotinib
Sensitive
:
D
crizotinib
Sensitive: D – Preclinical
crizotinib
Sensitive
:
D
NF1 underexpression
Neuroblastoma
NF1 underexpression
Neuroblastoma
binimetinib
Sensitive: D – Preclinical
binimetinib
Sensitive
:
D
binimetinib
Sensitive: D – Preclinical
binimetinib
Sensitive
:
D
MYCN amplification + ALK F1174L
Neuroblastoma
MYCN amplification + ALK F1174L
Neuroblastoma
lorlatinib
Sensitive: D – Preclinical
lorlatinib
Sensitive
:
D
lorlatinib
Sensitive: D – Preclinical
lorlatinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login